Congress targets syphilis crisis in pregnant women with Medicaid guidance
H.R. 3866 — Maternal and Infant Syphilis Prevention Act · Filed by Juan Ciscomani (R-AZ) · 4 cosponsors · Introduced Jun 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Secretary of Health and Human Services to issue guidance within 12 months on best practices for screening and treating congenital syphilis (syphilis transmitted from mother to infant) under Medicaid and the Children's Health Insurance Program (CHIP). The guidance covers expanded screening for pregnant women and newborns, provider and patient education, telehealth integration, third-trimester and delivery-time testing, and treatment improvements. HHS must report back to Congress within 2 years on implementation.
Why we flagged it
The bill's operative mechanism is a directive to HHS to issue non-binding guidance on best practices for congenital syphilis prevention under existing Medicaid and CHIP programs. It is a public health measure, not a regulatory change, appropriation, or private benefit.
What the text implies
- Guidance may increase Medicaid/CHIP spending on syphilis screening and treatment if states adopt recommendations, though the bill does not mandate adoption or appropriate funds.
- Telehealth integration guidance could expand access in rural and underserved areas but depends on state implementation and existing telehealth infrastructure.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers (antibiotics for syphilis treatment); diagnostic testing companies (syphilis screening tests); telehealth service providers (if states adopt telehealth recommendations)